Hypercalcaemia is common in malignant disease and complicates approximately 5-10% of all cancers. Hypercalcaemia may arise as a result of direct infiltration of bone, by local osteolysis or indirectly as a result of a humoral mechanism. In recent years there have been significant advances in our understanding of the biochemical processes that cause hypercalcaemia in malignancy, such that the factors involved in local osteolysis and in the evolution of humoral hypercalcaemia have now been delineated.
A number of different cytokines have been implicated in the development of hypercalcaemia as a result of local osteolysis. These osteoclast activating factors which are released locally by metastatic tumour and stimulate osteoclastic resorption of bone, include prostaglandin E2 (Greaves et al., 1980) , interleukin 1, (Dewhirst et al., 1985) , tumour necrosis factors alpha (cachectin) (Tashjian et al., 1987) and beta (lymphotoxin) (Bertolini et al., 1986) , epidermal growth factor (Lorenzo et al., 1986) and transforming growth factor beta (Sato et al., 1989) . It is probable that interleukin 1, epidermal growth factor and the tumour necrosis factors are the most important of these aetiological agents as the release of macrophage colony stimulating factor by osteoblasts is enhanced by these factors (Felix et al., 1989) . Since osteoclasts are derived from a haematopoietic stem cell progenitor, this release of macrophage colony stimulating factor may be fundamental to osteoclastic bone resorption.
Humoral hypercalcaemia was described in 1941 by Albright, but it has only been within the past 2 years that the humoral factor causing hypercalcaemia has been characterised. In the 1970s hypercalcaemia was thought to result from the ectopic production of parathyroid hormone (Mundy et al., 1984) but this hypothesis remained unproven because parathyroid hormone antisera failed to demonstrate excessive secretion of parathyroid hormone in patients with humoral hypercalcaemia (Goltzman et al., 1981) . In addition, low serum concentrations of 1,25 vitamin D3, bone resorption and urinary cyclic AMP levels failed to reflect excess parathyroid hormone activity (Rosol & Capen, 1988) and no parathyroid hormone mRNA was found in the tumours of patients with humoral hypercalcaemia (Simpson et al., 1983) .
Recently, a peptide derived from human tumours associated with humoral hypercalcaemia has been sequenced (Burtis et al., 1987 Moseley et al., 1987 . Polyadenylated RNA from a renal carcinoma from a patient with this syndrome was used to construct a cDNA library which was screened with a codon-preference oligonucleotide, synthesised on the basis of a partial N-terminal amino acid sequence from a human tumour derived peptide and a 2.0 kilobase cDNA was identified. The cDNA encoded a 177 amino acid prohormone which consisted of a 36 amino acid leader sequence that is cleaved to produce a 141 amino acid, mature peptide, parathyroid hormone related peptide. The first 13 amino acids of the mature peptide have sequence homology with parathyroid hormone, and the N-terminal sequence is thought to be the parathyroid hormone receptor binding region (Habener et al., 1984) . Parathyroid hormone related peptide was found to be expressed in most normal human tissue where its role is undetermined (Mangin et al., 1988) . The gene for parathyroid hormone related peptide has been mapped to the short arm of chromosome 12 and this is in contrast to the parathyroid hormone gene which has been mapped to the short arm of chromosome 11 (Mangin et al., 1989) . The gene for parathyroid hormone related peptide is complex and contains a six exon, 12 kilobase, single copy sequence, encoding up to five mRNA species. Exons 2, 3 and 4 are similar to the parathyroid hormone gene (Mangin et al., 1989) .
A recently developed radioimmunoassay for parathyroid hormone related peptide was used to screen patients with hypercalcaemia associated malignancy and the results contrasted with patients who were normocalcaemic and had malignant disease, patients with primary hyperparathyroidism and normal controls. Parathyroid hormone related peptide was elevated in 19 of 39 (49%) patients with malignant hypercalcaemia, 12 of 74 (16%) of normocalcaemic patients with malignancy, four of 20 patients (20%) with hyperparathyroidism, but in none of 22 normal controls (Henderson et al., 1989) .
We have treated a patient with humoral hypercalcaemia associated with a phaeochromocytoma. In this patient, hypercalcaemia was related to elevated levels of parathyroid hormone related peptide. Treatment with diphosphonates failed to result in normocalcaemia. Treatment with octreotide, a somatostatin analogue, resulted in normocalcaemia consequent to a reduction in serum parathyroid hormone related peptide levels (Harrison et al., 1990) . The response was transitory, but may provide an insight into the regulatory control of hypercalcaemia in malignant disease, and suggests potential future therapeutic manoeuvres.
As a result of scientific advances, parathyroid hormone related peptide has been clearly established as an important mechanism for malignant hypercalcaemia, pointing the way to new approaches. to the treatment of this condition.
